In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 5.98 below Olema Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 55 other companies have achieved higher Quick Ratio than Olema Pharmaceuticals Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 0 to 238.

Explain Quick Ratio?
How much Cash & cash equivalents OLMA�s has?
What are OLMA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/OLMA/financial-strength

https://api.csimarket.com/api/v1/companies/OLMA/fundamentals

https://api.csimarket.com/api/v1/companies/OLMA/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

OLMA Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	66.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	25.78 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	5.98	Subscribe	Subscribe	Subscribe	Subscribe
OLMA's Total Ranking	# 238	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	30.59 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-52.63 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 56
Healthcare Sector	# 82
Overall Market	# 238

Quick Ratio Statistics
High	Average	Low
114.3	22.38	7
(Dec 31 2020)		(Sep 30 2024)

Financial Statements
Olema Pharmaceuticals Inc 's Current Liabilities	$ 69 Millions	Visit OLMA's Balance sheet
Olema Pharmaceuticals Inc 's Cash & cash equivalent	$ 414 Millions	Visit OLMA's Balance sheet
Source of OLMA's Sales		Visit OLMA's Sales by Geography

Cumulative Olema Pharmaceuticals Inc 's Quick Ratio

OLMA's Quick Ratio for the trailling 12 Months

OLMA Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	54.42 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	51.43 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	10.43	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3373	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	14.31 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	3.83 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to OLMA Financial Strength Comparisons >> Go to Compare OLMA Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $69.23 millions, cumulative Quick Ratio decreased to 10.43 below the Olema Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 413 other companies have achieved higher Quick Ratio than Olema Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 0 to 3373.

Explain Quick Ratio?
How much Cash & cash equivalents OLMA�s has?
What are OLMA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 414
Healthcare Sector	# 839
Within the Market	# 3373

trailing twelve months Quick Ratio Statistics
High	Average	Low
39.51	15.85	9.08
(Dec 31 2021)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Keros Therapeutics Inc	16.36	$ 259.464 Millions	$ 15.858 Millions
Design Therapeutics Inc	16.36	$ 208.608 Millions	$ 12.753 Millions
Whitehawk Therapeutics Inc	16.25	$ 169.672 Millions	$ 10.441 Millions
Palvella Therapeutics Inc	15.85	$ 236.680 Millions	$ 14.928 Millions
Jade Biosciences Inc	15.70	$ 475.706 Millions	$ 30.293 Millions
Avalo Therapeutics Inc	15.63	$ 392.966 Millions	$ 25.135 Millions
Bioage Labs Inc	14.91	$ 283.637 Millions	$ 19.027 Millions
Damora Therapeutics Inc	14.72	$ 528.478 Millions	$ 35.892 Millions
Sellas Life Sciences Group Inc	14.51	$ 134.711 Millions	$ 9.286 Millions
Protagonist Therapeutics inc	14.42	$ 800.064 Millions	$ 55.464 Millions
Praxis Precision Medicines Inc	14.20	$ 745.323 Millions	$ 52.498 Millions
Tenax Therapeutics Inc	13.61	$ 113.700 Millions	$ 8.355 Millions
Ensysce Biosciences Inc	13.56	$ 29.671 Millions	$ 2.189 Millions
Corvus Pharmaceuticals Inc	13.25	$ 204.252 Millions	$ 15.418 Millions
Erasca Inc	13.10	$ 643.696 Millions	$ 49.122 Millions
Stablecoin Development Corporation	13.01	$ 7.153 Millions	$ 0.550 Millions
Uniqure N v	12.78	$ 768.430 Millions	$ 60.142 Millions
Rhythm Pharmaceuticals Inc	12.62	$ 320.944 Millions	$ 25.438 Millions
Assembly Biosciences Inc	12.61	$ 314.262 Millions	$ 24.921 Millions
Dyne Therapeutics Inc	12.53	$ 1,134.386 Millions	$ 90.545 Millions
Sensei Biotherapeutics Inc	12.44	$ 174.795 Millions	$ 14.049 Millions
Crescent Biopharma Inc	12.32	$ 289.357 Millions	$ 23.490 Millions
Spyre Therapeutics Inc	12.24	$ 82.727 Millions	$ 6.760 Millions
Edgewise Therapeutics inc	12.10	$ 1,743.893 Millions	$ 144.106 Millions
Obsidian Therapeutics, Inc.	11.77	$ 214.905 Millions	$ 18.264 Millions
Structure Therapeutics Inc	11.62	$ 1,244.661 Millions	$ 107.104 Millions
Kairos Pharma Ltd	11.60	$ 5.741 Millions	$ 0.495 Millions
Immunome Inc	11.27	$ 461.582 Millions	$ 40.966 Millions
Korro Bio Inc	11.06	$ 165.015 Millions	$ 14.923 Millions
Curanex Pharmaceuticals Inc	11.02	$ 1.580 Millions	$ 0.143 Millions

Date modified: 2026-11-11T13:54:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.